What is Elpiscience Biopharma?
Elpiscience Biopharma is a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of next-generation cancer immunotherapies. Founded in 2017 and headquartered in Shanghai, the company leverages a robust R&D framework to address unmet medical needs in oncology. By focusing on innovative therapeutic modalities, Elpiscience aims to redefine the standard of care for patients globally. Its market position is bolstered by a deep commitment to scientific rigor and a strategic focus on high-impact, immune-modulating drug candidates that target the tumor microenvironment.
How much funding has Elpiscience Biopharma raised?
Elpiscience Biopharma has raised a total of $225M across 3 funding rounds:
Series A
$20M
Series B
$100M
Series C
$105M
Series A (2017): $20M with participation from Lilly Asia Ventures
Series B (2019): $100M led by Hyfinity Investments
Series C (2021): $105M supported by Maison Capital, Cormorant Asset Management, Greater Bay Area Homeland Development Fund, Superstring Capital, and Pluto Connection Limited
Key Investors in Elpiscience Biopharma
Lilly Asia Ventures
Lilly Asia Ventures is a premier biomedical venture capital firm with a global footprint, specializing in supporting entrepreneurs who develop breakthrough products to improve human health.
Maison Capital
Maison Capital is an investment firm that emphasizes long-term perspectives and in-depth research, focusing on creating wealth and improving quality of life through strategic partnerships.
Cormorant Asset Management
Cormorant Asset Management is a prominent life sciences investment firm that utilizes fundamental scientific principles to provide financial resources to innovative biotech companies.
What's next for Elpiscience Biopharma?
With the successful closure of its latest funding cycle, Elpiscience Biopharma is well-positioned to advance its lead candidates through pivotal clinical trials. The strategic allocation of these funds will likely prioritize the expansion of its internal research capabilities and the acceleration of its global clinical development programs. As the company matures, it is expected to seek further partnerships and potential licensing opportunities to maximize the therapeutic reach of its pipeline. The focus remains on achieving key regulatory milestones and demonstrating clinical efficacy, which will be essential for long-term value creation in the highly competitive biopharma sector.
See full Elpiscience Biopharma company page
